AVDL Avadel Pharmaceuticals ADS

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

DUBLIN, Ireland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 9, 2023, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2023.

A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, . A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call and are advised to do so at least 10 minutes prior to joining the call.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit .

Investor Contact:

Courtney Turiano

Stern Investor Relations, Inc.



(212) 698-8687

Media Contact:

Lesley Stanley

Real Chemistry



(609) 273-3162



EN
02/08/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avadel Pharmaceuticals ADS

 PRESS RELEASE

Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upho...

Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit (the “Appeals Court”) affirmed a prior decision of the U.S. District Court for the District of Columbia (the “District Court”) in favor of the U.S. Food and Drug Admin...

 PRESS RELEASE

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule ...

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, June 16, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two new employees to purchase 9,600 ordinary shares under Avadel’s 2021 Inducement Plan. In addition, effective as of May 13, 2025, the Compensation Committee of Avadel’s Board of Directors approved a grant of non-statutory options to Susa...

 PRESS RELEASE

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for L...

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ ma...

 PRESS RELEASE

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate)...

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025 – 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – Data reflecting the therapeutic results of LUMRYZ treatment in people with narcolepsy across clinical as well as real-world settings will be presented – DUBLIN, Ireland, May 29, 2025 (GLOBE NE...

 PRESS RELEASE

Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare C...

Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference DUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 10:30 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, , for 90 days following the conference. Ab...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch